Tags

Type your tag names separated by a space and hit enter

Infectious complications during autotransplantation.
Hematol Oncol Clin North Am 1993; 7(3):717-35HO

Abstract

Bacterial and fungal infections are the most common cause of morbidity and mortality following autologous marrow transplant. An understanding of defects in host defense and the sources of bacterial and fungal infections allows a rational approach to controlling infections through prophylactic and empiric treatment. Recent availability of growth factors, broad-spectrum antibiotics, monoclonal antibodies to endotoxin, new antiviral agents, and new antifungal agents have enhanced our ability to successfully support patients through high-dose therapy and autologous stem cell reinfusion.

Authors+Show Affiliations

Department of Internal Medicine, University of Nebraska Medical Center, Omaha.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

8344887

Citation

Reed, E C.. "Infectious Complications During Autotransplantation." Hematology/oncology Clinics of North America, vol. 7, no. 3, 1993, pp. 717-35.
Reed EC. Infectious complications during autotransplantation. Hematol Oncol Clin North Am. 1993;7(3):717-35.
Reed, E. C. (1993). Infectious complications during autotransplantation. Hematology/oncology Clinics of North America, 7(3), pp. 717-35.
Reed EC. Infectious Complications During Autotransplantation. Hematol Oncol Clin North Am. 1993;7(3):717-35. PubMed PMID: 8344887.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Infectious complications during autotransplantation. A1 - Reed,E C, PY - 1993/6/1/pubmed PY - 1993/6/1/medline PY - 1993/6/1/entrez SP - 717 EP - 35 JF - Hematology/oncology clinics of North America JO - Hematol. Oncol. Clin. North Am. VL - 7 IS - 3 N2 - Bacterial and fungal infections are the most common cause of morbidity and mortality following autologous marrow transplant. An understanding of defects in host defense and the sources of bacterial and fungal infections allows a rational approach to controlling infections through prophylactic and empiric treatment. Recent availability of growth factors, broad-spectrum antibiotics, monoclonal antibodies to endotoxin, new antiviral agents, and new antifungal agents have enhanced our ability to successfully support patients through high-dose therapy and autologous stem cell reinfusion. SN - 0889-8588 UR - https://www.unboundmedicine.com/medline/citation/8344887/Infectious_complications_during_autotransplantation_ L2 - https://medlineplus.gov/bonemarrowtransplantation.html DB - PRIME DP - Unbound Medicine ER -